| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 470 | 2021 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 418 | 2020 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 250 | 2017 |
| Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German … P Albers, SI Park, G Niegisch, G Fechner, U Steiner, J Lehmann, ... Annals of Oncology 22 (2), 288-294, 2011 | 146 | 2011 |
| Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective … G Sonpavde, GR Pond, R Fougeray, TK Choueiri, AQ Qu, DJ Vaughn, ... European urology 63 (4), 717-723, 2013 | 125 | 2013 |
| The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells J Heubach, J Monsior, R Deenen, G Niegisch, T Szarvas, C Niedworok, ... Molecular cancer 14, 1-17, 2015 | 120 | 2015 |
| Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers G Niegisch, J Knievel, A Koch, C Hader, U Fischer, P Albers, WA Schulz Urologic Oncology: Seminars and Original Investigations 31 (8), 1770-1779, 2013 | 99 | 2013 |
| Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive … A Bamias, K Tzannis, LC Harshman, SJ Crabb, YN Wong, SK Pal, ... Annals of Oncology 29 (2), 361-369, 2018 | 81 | 2018 |
| Effects of novel HDAC inhibitors on urothelial carcinoma cells A Kaletsch, M Pinkerneil, MJ Hoffmann, AA Jaguva Vasudevan, C Wang, ... Clinical epigenetics 10, 1-18, 2018 | 69 | 2018 |
| Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma G Sonpavde, GR Pond, TK Choueiri, S Mullane, G Niegisch, P Albers, ... European Urology 69 (4), 634-641, 2016 | 69 | 2016 |
| Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors G Sonpavde, J Manitz, C Gao, D Tayama, C Kaiser, D Hennessy, ... The Journal of urology 204 (6), 1173-1179, 2020 | 66 | 2020 |
| A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first-and second-line treatment in locally advanced and metastatic … G Niegisch, H Gerullis, SW Lin, J Pavlova, A Gondos, A Rudolph, G Haas, ... Journal of Cancer 9 (8), 1337, 2018 | 66 | 2018 |
| Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international … A Necchi, G Sonpavde, SL Vullo, D Giardiello, A Bamias, SJ Crabb, ... European urology 71 (2), 281-289, 2017 | 63 | 2017 |
| Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate HJ Lavery, KD Stensland, G Niegisch, P Albers, MJ Droller The Journal of urology 191 (4), 898-906, 2014 | 62 | 2014 |
| Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype S Selinski, M Blaszkewicz, ML Lehmann, D Ovsiannikov, O Moormann, ... Pharmacogenetics and genomics 21 (10), 673-678, 2011 | 61 | 2011 |
| Evaluation of the therapeutic potential of the novel isotype specific HDAC inhibitor 4SC-202 in urothelial carcinoma cell lines M Pinkerneil, MJ Hoffmann, H Kohlhof, WA Schulz, G Niegisch Targeted oncology 11, 783-798, 2016 | 60 | 2016 |
| HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma U Kreimer, WA Schulz, A Koch, G Niegisch, W Goering Frontiers in Oncology 3, 255, 2013 | 59 | 2013 |
| Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms M Pinkerneil, MJ Hoffmann, R Deenen, K Koehrer, T Arent, WA Schulz, ... Molecular cancer therapeutics 15 (2), 299-312, 2016 | 58 | 2016 |
| Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex D Schluetermann, MA Skowron, N Berleth, P Boehler, J Deitersen, ... Urologic Oncology: Seminars and Original Investigations 36 (4), 160. e1-160. e13, 2018 | 53 | 2018 |
| Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells L Rosik, G Niegisch, U Fischer, M Jung, WA Schulz, MJ Hoffmann Cancer biology & therapy 15 (6), 742-757, 2014 | 53 | 2014 |
